Clinical trial
A Phase I Trial Evaluating the Safety of Consolidative Infusions of CD19-Specific Chimeric Antigen Receptor (CAR) T Cells Following T-cell Depleted Allogeneic Transplantation for High Risk B-cell Malignancies
NCT04556266 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Trial Evaluating the Safety of Consolidative Infusions of CD19-Specific Chimeric Antigen Receptor (CAR) T Cells Following T-cell Depleted Allogeneic Transplantation for High Risk B-cell Malignancies
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Phase
- Phase 1
- Overall status
- Withdrawn
- Start date
- July 1, 2021
- Completion date
- March 1, 2022
- Enrollment
- 0 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.